scispace - formally typeset
R

Raquel de Oliveira Vilhena

Researcher at Federal University of Paraná

Publications -  25
Citations -  595

Raquel de Oliveira Vilhena is an academic researcher from Federal University of Paraná. The author has contributed to research in topics: Carbidopa & Entacapone. The author has an hindex of 7, co-authored 22 publications receiving 269 citations.

Papers
More filters
Journal ArticleDOI

Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19.

TL;DR: RT-PCR remains the gold standard for the diagnosis of COVID-19 in sputum samples and the combination of different diagnostic tests is highly recommended to achieve adequate sensitivity and specificity.
Journal ArticleDOI

Occurrence of antibiotics and antibiotic resistant bacteria in subtropical urban rivers in Brazil

TL;DR: Investigation of the presence of antibiotics of different classes and associated resistant bacteria, in water samples taken from urban river waters in Curitiba, Brazil found antibiotics came from domestic effluents and may be contributing to the spread of bacterial resistance.
Journal ArticleDOI

Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.

TL;DR: A HPLC-MS/MS method capable of simultaneously determining levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma was developed and validated and successfully applied in plasma patients with Parkinson's disease using Stalevo®.
Journal ArticleDOI

A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.

TL;DR: The results indicated that this new method using HILIC mode and LC-MS/MS for simultaneous determination of carbidopa, levodopa, and its metabolites in human plasma is suitable for therapeutic drug monitoring in Parkinson's disease patients.
Journal ArticleDOI

Risk factors associated with delay in diagnosis and mortality in patients with COVID-19 in the city of Rio de Janeiro, Brazil

TL;DR: Delays in diagnosis and risk factors for death from COVID-19 were associated with male gender, age under 60 years, and patients living in regions with lower SDI, and delays superior to eight days to diagnosis increased mortality rates.